Next Article in Journal
Advances in Cerebellar TMS Therapy: An Updated Systematic Review on Multi-Session Interventions
Previous Article in Journal
Obstructive Sleep Apnea and Outcomes in Cardiac Surgery: A Systematic Review with Meta-Analytic Synthesis (PROSPERO CRD420251049574)
Previous Article in Special Issue
Hypothermia Mitigates Renal Fibrosis Through the Upregulation of PGC-1α After Ischemia–Reperfusion Injury
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

The Effect of Dapagliflozin, a Sodium–Glucose Co-Transporter 2 Inhibitor, on Vancomycin-Induced Nephrotoxicity in Rats

1
Department of Internal Medicine, Faculty of Medicine, Çukurova University, 01330 Adana, Sarıçam, Turkey
2
Department of Nephrology, Faculty of Medicine, Çukurova University, 01330 Adana, Sarıçam, Turkey
3
Department of Virology, Faculty of Ceyhan Veterinary Medicine, Çukurova University, 01930 Adana, Ceyhan, Turkey
4
Department of Pathology, Faculty of Medicine, Çukurova University, 01330 Adana, Sarıçam, Turkey
5
Department of Histology and Embriology, Faculty of Medicine, Çukurova University, 01330 Adana, Sarıçam, Turkey
6
Department of Public Health, Faculty of Medicine, Çukurova University, 01330 Adana, Sarıçam, Turkey
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Biomedicines 2025, 13(7), 1582; https://doi.org/10.3390/biomedicines13071582 (registering DOI)
Submission received: 29 April 2025 / Revised: 4 June 2025 / Accepted: 24 June 2025 / Published: 27 June 2025

Abstract

Background/Objectives: Vancomycin-induced nephrotoxicity (VIN) remains a significant clinical challenge, with no effective nephroprotective agent currently established. This study aimed to evaluate the protective effects of the sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (DAPA) against VIN in a Wistar albino rat model. Methods: Rats were randomly assigned to four groups: control, VA (vancomycin), DAPA (dapagliflozin), and VA+DAPA. Renal function was assessed by measuring serum urea and creatinine. Oxidative stress markers [malondialdehyde (MDA), total oxidant status (TOS), and myeloperoxidase (MPO)], antioxidant enzyme activities [total antioxidant status (TAS), glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD)], apoptotic mediators (Bax, Bcl-2, and caspase-3), and pro-inflammatory cytokines [tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6)] were evaluated. Histopathological and immunohistochemical analyses of kidney tissues were also performed. Results: Administration of VA led to significant renal dysfunction, increased oxidative stress, heightened apoptotic activity, and notable histopathological damage. Co-administration of DAPA with VA significantly reduced serum urea and creatinine levels and decreased caspase-3 activity and was associated with a trend toward reduction in both MDA levels and TNF-α expression, as well as the amelioration of histopathological renal injury. However, reductions in IL-1β and IL-6 levels were not statistically significant. Overall, these findings indicate that DAPA exerts nephroprotective effects against VIN by modulating oxidative stress, inflammation, and apoptotic pathways. Conclusions: Dapagliflozin may serve as a potential protective agent against vancomycin-induced nephrotoxicity. Further long-term and large-scale clinical studies are warranted to validate these preclinical findings and explore their therapeutic implications.
Keywords: Vancomycin-induced nephrotoxicity; Dapagliflozin; nephroprotective effect Vancomycin-induced nephrotoxicity; Dapagliflozin; nephroprotective effect
Graphical Abstract

Share and Cite

MDPI and ACS Style

Tan, S.; Kaya, B.; Akburak, E.; Avci, C.; Eren Ates, K.; Gonlusen, G.; Sapmaz Ercakalli, T.; Mete, B. The Effect of Dapagliflozin, a Sodium–Glucose Co-Transporter 2 Inhibitor, on Vancomycin-Induced Nephrotoxicity in Rats. Biomedicines 2025, 13, 1582. https://doi.org/10.3390/biomedicines13071582

AMA Style

Tan S, Kaya B, Akburak E, Avci C, Eren Ates K, Gonlusen G, Sapmaz Ercakalli T, Mete B. The Effect of Dapagliflozin, a Sodium–Glucose Co-Transporter 2 Inhibitor, on Vancomycin-Induced Nephrotoxicity in Rats. Biomedicines. 2025; 13(7):1582. https://doi.org/10.3390/biomedicines13071582

Chicago/Turabian Style

Tan, Seyhmus, Bulent Kaya, Ercan Akburak, Cagri Avci, Kivilcim Eren Ates, Gulfiliz Gonlusen, Tugce Sapmaz Ercakalli, and Burak Mete. 2025. "The Effect of Dapagliflozin, a Sodium–Glucose Co-Transporter 2 Inhibitor, on Vancomycin-Induced Nephrotoxicity in Rats" Biomedicines 13, no. 7: 1582. https://doi.org/10.3390/biomedicines13071582

APA Style

Tan, S., Kaya, B., Akburak, E., Avci, C., Eren Ates, K., Gonlusen, G., Sapmaz Ercakalli, T., & Mete, B. (2025). The Effect of Dapagliflozin, a Sodium–Glucose Co-Transporter 2 Inhibitor, on Vancomycin-Induced Nephrotoxicity in Rats. Biomedicines, 13(7), 1582. https://doi.org/10.3390/biomedicines13071582

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop